Drug intelligence / Profile preview

Aligastril

Development stage
Unknown
Lead developer
Laboratori Aliveda
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Aligastril is a multi-ingredient dietary supplement developed by Laboratori Aliveda for the management of gastritis, hyperacidity, functional dyspepsia, NSAID-induced gastropathy, and gastroesophageal reflux disease (GERD). It is available in two oral formulations: a ready-to-use gel and a dissolvable powder. The synergistic formulation combines sodium alginate, melatonin, and chamomile extract, with the powder version also containing sodium bicarbonate and chitosan. Sodium alginate reacts with gastric acid to form a viscous gel raft that floats on top of the stomach contents, creating a physical barrier that mechanically prevents acid reflux. Melatonin stimulates gastrin release to increase lower esophageal sphincter (LES) tone, inhibits gastric acid secretion, and promotes mucosal healing. Chamomile extract provides soothing, anti-inflammatory, and spasmolytic effects on the gastrointestinal tract, while sodium bicarbonate acts as a rapid antacid to neutralize excess stomach acid.

Brand names
AligastrilAligastril Gel
Other names
Aligastril gelAligastril powder
02

Targets

MTNR1A (MT1)

Beyond the preview

Go deeper on Aligastril.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aligastril.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call